Recent studies involving AKI patients hospitalized with COVID-19 have shed light on the association between urinary EGF and adverse kidney outcomes, suggesting the potential for use of urinary EGF as a tool for tracking progression and recovery in kidney disease patients [54]. The gene discussed is EGF; the disease is COVID-19.